Variable | All triple negatives; n = 97 (%) | Triple negatives with sufficient FU; n = 71 (%) |
---|---|---|
Age (years) | Â | Â |
<41 | 24 (25) | 18 (25) |
41–50 | 33 (34) | 30 (42) |
>50 | 40 (41) | 23 (32) |
Tumor size (cm) | Â | Â |
≤2.0 | 34 (35) | 23 (32) |
>2.0 | 63 (65) | 48 (68) |
Number of tumor positive lymph nodes | Â | Â |
0 | 54 (56) | 35 (49) |
1–3 | 29 (30) | 26 (37) |
>3 | 14 (14) | 10 (14) |
Tumor subtype | Â | Â |
Adenoid cystic | 4 (4) | NA |
Apocrine | 7 (7) | 7 (10) |
Ducto-lobular | 1 (1) | NA |
IDC (nos) | 81 (83) | 63 (89) |
ILC | 1 (1) | 1 (1) |
Metaplastic | 3 (3) | NA |
Tumor shape | Â | Â |
Multi-nodular | 4 (4) | 4 (6) |
Stellate | 17 (18) | 12 (17) |
Sharply demarcated/lobulated | 76 (78) | 55 (76) |
Histological grade | Â | Â |
1 | 2 (2) | 2 (3) |
2 | 8 (8) | 4 (6) |
3 | 83 (86) | 65 (92) |
Adenoid cystic carcinoma not graded | 4 (4) | NA |
DCIS component around tumor | Â | Â |
None | 79 (81) | 56 (79) |
Minimal | 10 (10) | 8 (11) |
Moderate | 8 (8) | 7 (10) |
Extensive | NA | NA |
DCIS differentiation grade | Â | Â |
Well | 1 (6) | 1 (7) |
Moderate | NA | NA |
Poor | 17 (94) | 14 (93) |
LCIS component | Â | Â |
None | 93 (96) | 67 (94) |
Present | 4 (4) | 4 (6) |
Vascular invasion | Â | Â |
None | 84 (87) | 59 (83) |
Present | 13 (13) | 12 (17) |
Lymphocytic infiltrate | Â | Â |
None | 8 (8) | 4 (6) |
Minimal | 40 (41) | 34 (48) |
Moderate | 33 (34) | 25 (35) |
Extensive | 12 (12) | 8 (11) |
Adenoid cystic carcinoma not graded | 4 (4) | NA |
Central fibrotic zone | Â | Â |
None | 44 (45) | 31 (44) |
Present | 49 (51) | 40 (56) |
Adenoid cystic carcinoma not graded | 4 (4) | NA |
KRT5/6 | Â | Â |
Negative (0% staining) | 21 (22) | 16 (23) |
Positive (> 0% staining) | 74 (76) | 53 (75) |
Unknown | 2 (2) | 2 (3) |
p53 | Â | Â |
Negative (< 50% staining) | 47 (49) | 33 (47) |
Positive (> 49% staining) | 48 (50) | 36 (51) |
Unknown | 2 (2) | 2 (3) |
EGFR | Â | Â |
Negative (0% staining) | 69 (71) | 58 (82) |
Positive (> 0% staining) | 26 (27) | 11 (16) |
Unknown | 2 (2) | 2 (3) |
KIT | Â | Â |
Negative (0% staining) | 58 (60) | 39 (55) |
Positive (> 0% staining) | 37 (38) | 30 (42) |
Unknown | 2 (2) | 2 (3) |
Treatment of primary tumor | Â | Â |
Breast-conservation | 61 (63) | 45 (63) |
Mastectomy | 36 (37) | 26 (37) |
Adjuvant radiotherapy | Â | Â |
Yes | 85 (88) | 65 (92) |
No | 12 (12) | 6 (8) |
Adjuvant systemic therapy | Â | Â |
Chemotherapy | 47 (48) | 37 (52) |
Endocrine therapy | 13 (13) | 11 (15) |
Chemotherapy and endocrine therapy | 4 (4) | 4 (6) |
None | 33 (34) | 19 (27) |
Metastasis as first event | Â | Â |
Yes | NA | 17 (24) |
No | NA | 54 (76) |